TY - JOUR T1 - Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer. JO - Journal of Clinical Oncology PY - 2020/05/20 AU - Tuthill M AU - Cappuccini F AU - Bryant RJ AU - Poulton I AU - Pollock E AU - Carter L AU - Verrill C AU - Meier A AU - Schmidt G AU - Catto JWF AU - Evans T et al ED - DO - DOI: 10.1200/jco.2020.38.15_suppl.tps3170 PB - American Society of Clinical Oncology (ASCO) VL - 38 IS - 15_suppl SP - TPS3170 EP - TPS3170 Y2 - 2025/07/20 ER -